Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,235 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Change in Management
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI Listing Regulations detailing the outcome of a Board Meeting, including approval of audited financial results, dividend recommendation, appointment of internal auditor, and AGM scheduling. It is not the full annual report (10-K or IR), nor is it a standalone audit report. It is not a director change notice (MANG), earnings release, management discussion, or AGM material, but a regulatory announcement to stock exchanges of meeting outcomes. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-12 English
General Updates
Regulatory Filings Classification · 85% confidence The document is a formal board meeting outcome announcement filed under SEBI LODR Regulations 30 and 33, informing stock exchanges of the approval of audited standalone and consolidated financial results, declaration of dividend, auditor re-appointment, and AGM details. Although the audit reports are attached in full, the primary purpose is a regulatory announcement of board resolutions and result publication. There is no change in management, no proxy materials, and it is not a full annual report (10-K) nor a press‐style earnings release. Therefore, it falls under the general Regulatory Filings (RNS) category.
2026-05-12 English
Recommended Final Dividend for the financial year ended March 31, 2026, subject to approval of the shareholders in the forthcoming 41st Annual General Meeting of the Company
Earnings Release Classification · 80% confidence The document is a stock‐exchange disclosure made under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulation 30 & 33) announcing the board meeting outcome. It conveys approval of audited standalone and consolidated financial results for the quarter/year ended March 31, 2026 (with auditor’s reports), declaration of dividend, scheduling of the AGM, etc. This is the standard earnings results announcement rather than the full annual report or an AGM notice. Hence it maps to an Earnings Release. FY 2026
2026-05-12 English
Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on May 12, 2026, the members has granted 1,80,000 stock options under Bliss GVS ....
Share Issue/Capital Change Classification · 75% confidence The document is a regulatory disclosure under SEBI Listing Regulations (Regulation 30) informing stock exchanges of an Employee Stock Options Plan grant, detailing the number of options, pricing, vesting, and other terms. This is a corporate action related to potential future issuance of shares under the ESOP, which constitutes a change in share capital. Therefore, it best fits the "Share Issue/Capital Change" category (SHA).
2026-05-12 English
General Updates
Regulatory Filings Classification · 80% confidence The document is a regulatory disclosure under SEBI Listing Regulations (Regulation 30) announcing the grant of employee stock options under the Company’s ESOP plan. It does not contain financial statements or performance data, nor is it a management change, earnings release, or formal proxy/remuneration statement. It is a routine corporate announcement filed with the exchanges. Thus, it falls under the general Regulatory Filings category (RNS).
2026-05-12 English
Please find attached herewith the audited standalone & consolidated financial results for the quarter and year ended March 31, 2026
Regulatory Filings Classification · 82% confidence The document is a compliance disclosure letter under SEBI LODR dated May 12, 2026, announcing the outcome of the Board meeting — namely approval of audited standalone and consolidated financial results, audit opinions, dividend recommendation, auditor re-appointment, and AGM scheduling. It is a regulatory stock-exchange filing rather than a full annual report, a call transcript, an interim/quarterly report, or a press-style earnings release. Accordingly, it is best classified under general regulatory filings.
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.